Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$1.95 -0.5%	$1.68	$1.33 ▼ $3.58	$91.87M	0.74	61,506 shs	1,898 shs
ADCT ADC Therapeutics	$3.62 -1.5%	$2.00	$1.05 ▼ $4.13	$355.06M	1.96	616,396 shs	829,699 shs
CMPX Compass Therapeutics	$2.41	$2.00	$0.77 ▼ $4.08	$333.26M	1.41	954,588 shs	746,462 shs
SLDB Solid Biosciences	$4.51 -1.5%	$3.26	$2.41 ▼ $10.37	$349.59M	2.22	1.15 million shs	1.23 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	0.00%	-2.01%	+10.17%	+10.08%	-32.99%
ADCT ADC Therapeutics	0.00%	-1.77%	+112.65%	+95.93%	+14.40%
CMPX Compass Therapeutics	0.00%	-3.60%	+19.31%	-2.03%	+100.83%
SLDB Solid Biosciences	0.00%	-0.66%	+74.13%	-11.39%	-43.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAG Adagene	2.6895 of 5 stars	3.3	5.0	2.7	1.7	0.0
ADCT ADC Therapeutics	2.5892 of 5 stars	3.5	3.0	3.2	0.8	0.6
CMPX Compass Therapeutics	3.5675 of 5 stars	4.6	1.0	2.7	5.0	0.0
SLDB Solid Biosciences	3.8666 of 5 stars	4.6	3.0	2.9	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	2.50	Moderate Buy	$8.00	310.26% Upside
ADCT ADC Therapeutics	3.00	Buy	$8.50	135.13% Upside
CMPX Compass Therapeutics	3.11	Buy	$13.13	444.61% Upside
SLDB Solid Biosciences	3.23	Buy	$14.90	230.38% Upside

Current Analyst Ratings Breakdown

Latest ADAG, SLDB, CMPX, and ADCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $10.00
6/6/2025	SLDB Solid Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
5/22/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$16.00
5/19/2025	SLDB Solid Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/16/2025	SLDB Solid Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$20.00 ➝ $17.00
5/16/2025	SLDB Solid Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$15.00 ➝ $10.00
5/16/2025	SLDB Solid Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$18.00 ➝ $17.00
5/15/2025	ADCT ADC Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$8.00 ➝ $8.00
5/13/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
4/28/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$103.20K	890.13	N/A	N/A	$1.61 per share	1.21
ADCT ADC Therapeutics	$75.82M	4.73	N/A	N/A	($1.93) per share	-1.87
CMPX Compass Therapeutics	$850K	392.07	N/A	N/A	$1.17 per share	2.06
SLDB Solid Biosciences	$8.09M	43.21	N/A	N/A	$6.27 per share	0.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$18.95M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/23/2025 (Estimated)
ADCT ADC Therapeutics	-$240.05M	-$1.45	N/A	N/A	N/A	-300.00%	N/A	-61.33%	8/5/2025 (Estimated)
CMPX Compass Therapeutics	-$42.49M	-$0.41	N/A	N/A	N/A	N/A	-32.37%	-30.67%	8/11/2025 (Estimated)
SLDB Solid Biosciences	-$96.01M	-$2.99	N/A	N/A	N/A	N/A	-58.75%	-47.84%	8/12/2025 (Estimated)

Latest ADAG, SLDB, CMPX, and ADCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A
5/14/2025	Q1 2025	ADCT ADC Therapeutics	-$0.38	-$0.36	+$0.02	-$0.36	$17.71 million	$23.03 million
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
3/27/2025	Q4 2024	ADCT ADC Therapeutics	-$0.35	-$0.29	+$0.06	-$0.29	$19.01 million	$19.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.08	2.50	N/A
ADCT ADC Therapeutics	N/A	4.92	4.68
CMPX Compass Therapeutics	N/A	31.84	31.84
SLDB Solid Biosciences	N/A	7.85	7.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
ADCT ADC Therapeutics	41.10%
CMPX Compass Therapeutics	68.43%
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
ADCT ADC Therapeutics	5.40%
CMPX Compass Therapeutics	29.80%
SLDB Solid Biosciences	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	260	47.11 million	34.89 million	Not Optionable
ADCT ADC Therapeutics	310	99.18 million	92.73 million	Optionable
CMPX Compass Therapeutics	20	138.28 million	98.38 million	Not Optionable
SLDB Solid Biosciences	100	77.52 million	35.05 million	Optionable

ADAG, SLDB, CMPX, and ADCT Headlines

Recent News About These Companies

Solid Biosciences Approves Equity Plan Amendment at Meeting

June 13 at 5:13 PM | tipranks.com

Analysts Offer Predictions for SLDB FY2026 Earnings

June 11, 2025 | americanbankingnews.com

Brokers Offer Predictions for SLDB FY2026 Earnings

June 10, 2025 | marketbeat.com

Solid Biosciences Inc. (NASDAQ:SLDB) Shares Sold by Two Sigma Investments LP

June 9, 2025 | marketbeat.com

Solid Biosciences' (SLDB) Market Outperform Rating Reaffirmed at JMP Securities

June 8, 2025 | americanbankingnews.com

Solid Biosciences' (SLDB) "Market Outperform" Rating Reiterated at JMP Securities

June 6, 2025 | marketbeat.com

Short Interest in Solid Biosciences Inc. (NASDAQ:SLDB) Increases By 27.6%

June 5, 2025 | americanbankingnews.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 3, 2025 | globenewswire.com

Solid Biosciences Inc. (NASDAQ:SLDB) Short Interest Update

June 3, 2025 | marketbeat.com

Millennium Management LLC Sells 397,321 Shares of Solid Biosciences Inc. (NASDAQ:SLDB)

June 1, 2025 | marketbeat.com

Solid Biosciences’ SWOT analysis: gene therapy stock poised for potential breakthrough

May 28, 2025 | investing.com

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of "Buy" by Brokerages

May 28, 2025 | marketbeat.com

Research Analysts Set Expectations for SLDB FY2025 Earnings

May 27, 2025 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Earns "Overweight" Rating from Cantor Fitzgerald

May 24, 2025 | marketbeat.com

Chardan Capital Has Lowered Expectations for Solid Biosciences (NASDAQ:SLDB) Stock Price

May 21, 2025 | marketbeat.com

Q1 Earnings Forecast for SLDB Issued By William Blair

May 21, 2025 | marketbeat.com

Truist maintains buy on Solid Biosciences stock, price target at $16

May 18, 2025 | investing.com

Dimensional Fund Advisors LP Purchases 192,714 Shares of Solid Biosciences Inc. (NASDAQ:SLDB)

May 18, 2025 | marketbeat.com

When Might Solid Biosciences Run Out Of Money?

May 17, 2025 | finance.yahoo.com

Solid Biosciences (NASDAQ:SLDB) Upgraded by Cantor Fitzgerald to "Strong-Buy" Rating

May 17, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG, SLDB, CMPX, and ADCT Company Descriptions

Adagene NASDAQ:ADAG

$1.95 -0.01 (-0.51%)

Closing price 06/13/2025 03:57 PM Eastern

Extended Trading

$1.95 +0.00 (+0.05%)

As of 06/13/2025 04:02 PM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

ADC Therapeutics NYSE:ADCT

$3.62 -0.06 (-1.50%)

Closing price 06/13/2025 03:59 PM Eastern

Extended Trading

$3.61 -0.01 (-0.14%)

As of 06/13/2025 07:47 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Compass Therapeutics NASDAQ:CMPX

$2.41 0.00 (0.00%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.42 +0.00 (+0.21%)

As of 06/13/2025 07:23 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Solid Biosciences NASDAQ:SLDB

$4.51 -0.07 (-1.53%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$4.48 -0.03 (-0.67%)

As of 06/13/2025 07:23 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time